Seer, Inc. (SEER)
Automate Your Wheel Strategy on SEER
With Tiblio's Option Bot, you can configure your own wheel strategy including SEER - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SEER
- Rev/Share 0.2899
- Book/Share 4.8269
- PB 0.4102
- Debt/Equity 0.0892
- CurrentRatio 14.251
- ROIC -0.2842
- MktCap 111378014.0
- FreeCF/Share -0.8181
- PFCF -2.4177
- PE -1.4052
- Debt/Assets 0.0786
- DivYield 0
- ROE -0.2648
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
The Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant Change
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own nearly 7.5% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following open letter to the Company's Board of Directors. *** February 23, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: The Board of Directors Members of the Board of Directors (the “Board”).
Read More
What Makes Seer, Inc. (SEER) a Strong Momentum Stock: Buy Now?
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Seer, Inc. (SEER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
After Plunging -16.81% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Negative
Seer (SEER) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
Down -10.53% in 4 Weeks, Here's Why Seer (SEER) Looks Ripe for a Turnaround
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Seer, Inc. (NASDAQ:SEER ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board David Horn - Chief Financial Officer and President Conference Call Participants Marta Zaremba - JPMorgan Jason Lai - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Seer Fourth Quarter and Full-Year 2024 Earnings Conference Call.
Read More
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.28 per share a year ago.
Read More
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteograph™ Product Suite Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteograph™ Product Suite
Read More
About Seer, Inc. (SEER)
- IPO Date 2020-12-04
- Website https://seer.bio
- Industry Biotechnology
- CEO Omid C. Farokhzad
- Employees 134